Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Revenue (2016 - 2025)

Historic Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $70.6 million.

  • Viridian Therapeutics, Inc.\DE's Revenue rose 8195813.95% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year increase of 2334006.62%. This contributed to the annual value of $302000.0 for FY2024, which is 382.17% down from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Revenue is $70.6 million, which was up 8195813.95% from $75000.0 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Revenue ranged from a high of $70.6 million in Q3 2025 and a low of $72000.0 during Q2 2023
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Revenue had a median value of $98000.0 in 2023 and averaged $4.0 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Revenue tumbled by 9397.49% in 2023 and then soared by 8195813.95% in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Revenue (Quarter) stood at $214000.0 in 2021, then tumbled by 50.93% to $105000.0 in 2022, then crashed by 31.43% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then surged by 97913.89% to $70.6 million in 2025.
  • Its Revenue stands at $70.6 million for Q3 2025, versus $75000.0 for Q2 2025 and $72000.0 for Q1 2025.